Cancers are a group of heterogeneous diseases characterized by the acquisition of
functional capabilities during the transition from a normal to a neoplastic state. Powerful …

Simple Summary CD3-bispecific antibody therapy is a form of immunotherapy that enables
soldier cells of the immune system to recognize and kill tumor cells. This type of therapy is …

T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with
hematologic malignancies; however, resistance and subsequent relapse remains a major …

Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell
precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30–50% of …

There have been major advances in the immunotherapy of cancer in recent years, including
the development of T cell engagers—antibodies engineered to redirect T cells to recognize …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved
in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL) …

Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

B cell progenitor acute lymphoblastic leukemia (B-ALL) treatment has been revolutionized
by T cell-based immunotherapies—including chimeric antigen receptor T cell therapy (CAR …

Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in treating
a variety of hematologic malignancies, but resistance to this treatment in some patients …